Global Lurasidone Hydrochloride Tablet Market Growth (Status and Outlook) 2024-2030

Global Lurasidone Hydrochloride Tablet Market Growth (Status and Outlook) 2024-2030

Lurasidone Hydrochloride Tablets is an oral atypical antipsychotic drug, mainly used to treat depressive episodes of schizophrenia and bipolar disorder. Its main ingredient is lurasidone hydrochloride.

The global Lurasidone Hydrochloride Tablet market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “Lurasidone Hydrochloride Tablet Industry Forecast” looks at past sales and reviews total world Lurasidone Hydrochloride Tablet sales in 2022, providing a comprehensive analysis by region and market sector of projected Lurasidone Hydrochloride Tablet sales for 2023 through 2029. With Lurasidone Hydrochloride Tablet sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Lurasidone Hydrochloride Tablet industry.

This Insight Report provides a comprehensive analysis of the global Lurasidone Hydrochloride Tablet landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Lurasidone Hydrochloride Tablet portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Lurasidone Hydrochloride Tablet market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Lurasidone Hydrochloride Tablet and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Lurasidone Hydrochloride Tablet.

United States market for Lurasidone Hydrochloride Tablet is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Lurasidone Hydrochloride Tablet is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Lurasidone Hydrochloride Tablet is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Lurasidone Hydrochloride Tablet players cover Sumitomo Pharma America, Inc., Dr. Reddy's Laboratories Limited, Teva Takeda Yakuhin Ltd., LTL Pharma Co., Ltd., Mylan Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Lurasidone Hydrochloride Tablet market by product type, application, key players and key regions and countries.

Segmentation by Type:
20mg
40mg

Segmentation by Application:
Hospital
Clinic
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
20mg
40mg

Segmentation by Application:
Hospital
Clinic
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sumitomo Pharma America, Inc.
Dr. Reddy's Laboratories Limited
Teva Takeda Yakuhin Ltd.
LTL Pharma Co., Ltd.
Mylan Pharmaceuticals
Organon LLC
Santen Pharmaceutical Co.,Ltd.
Hengrui Medicine
Teva Pharmaceutical Industries

Please note: The report will take approximately 2 business days to prepare and deliver.